Humoral and Cellular Immune Response Mechanisms

When a foreign antigen enters the body for the first time, it is processed by antigen-presenting cells (APCs), most notably dendritic cells, which migrate to regional lymph nodes and display antigen-derived peptides on their MHC class II surface proteins. Helper T cells with complementary receptors bind to these complexes and are activated. Activated helper T cells then present co-stimulatory signals to B cells carrying the matching antigen receptor, triggering B cell activation.

Activated B cells proliferate in the lymph node, a process called clonal expansion, generating thousands of daughter cells all bearing the same antigen specificity as the original B cell. Some daughter cells differentiate into plasma cells that immediately begin secreting antibody. The earliest antibodies in the primary response are IgM, a pentameric molecule with ten antigen-binding sites. IgM is efficient at activating complement and agglutinating particulate antigens, but its affinity for individual epitopes is modest.

Other daughter cells enter germinal centres in the lymph node where they undergo somatic hypermutation: random mutations introduced into the variable regions of their immunoglobulin genes. Cells whose mutated receptors bind antigen more tightly are selected for survival; those with lower affinity die. This process, affinity maturation, progressively increases the average binding strength of the antibodies produced. As the primary response proceeds, the antibody class switches from IgM to IgG through a process called class switching, driven by cytokine signals from helper T cells.

The timeline of the primary response matters for forensic antiserum production. Antibody does not appear in the circulation for approximately five to seven days after first injection of antigen. Titres peak at two to four weeks, then decline as plasma cells die. This lag and low initial yield are the reason a single antigen injection cannot produce a useful antiserum.

During the primary response, not all activated B cells differentiate into plasma cells. A subset becomes memory B cells: long-lived cells that persist in lymphoid tissue and bone marrow for years, even decades. They carry the antigen-specific receptor, have already undergone some affinity maturation, and are primed to respond rapidly on re-exposure.

When the same antigen is encountered again, memory B cells are activated within one to two days rather than the five to seven day lag of the primary response. They expand rapidly and differentiate into large numbers of plasma cells producing high-affinity IgG. The antibody titres achieved in a secondary response are typically ten to one hundred times higher than the peak primary titre. Affinity maturation continues through subsequent exposures, progressively tightening the antibody-antigen fit.

While B cells and antibodies handle threats in extracellular fluids, T cells handle intracellular pathogens and abnormal cells. Two major T cell subsets operate through distinct mechanisms. Helper T cells (CD4+) recognise antigen presented on MHC class II molecules, which are expressed mainly on professional APCs. Their activation drives cytokine release that amplifies both the humoral response (stimulating B cells) and the cellular response (activating cytotoxic T cells). Without helper T cell cooperation, protein antigens fail to generate full antibody responses and immunological memory is weak.

Cytotoxic T cells (CD8+) recognise antigen on MHC class I molecules, which are expressed on virtually all nucleated cells. When a CD8+ T cell identifies a target cell displaying a foreign or abnormal peptide, it releases perforin, which punches pores in the target cell membrane, and granzymes, which enter through those pores and trigger apoptosis. This mechanism eliminates virally infected cells and tumour cells.

In a forensic context, cellular immunity is most relevant through the MHC (major histocompatibility complex) antigen system, also called the HLA (human leukocyte antigen) system in humans. Before DNA profiling became available in the late 1980s, HLA typing of bloodstains was used in parentage testing and relationship testing. The HLA loci are highly polymorphic: the probability that two unrelated individuals share the same HLA profile is low, making HLA typing a useful discriminating tool. The forensic relevance of HLA has largely been superseded by STR-based DNA profiling, but the immune mechanisms underlying HLA diversity remain part of forensic immunology education because they explain the biology of tissue typing reagents and transplantation immunology used in medicolegal contexts.

The practical output of understanding immune response mechanisms is the ability to produce and evaluate antisera for forensic use. Antiserum production follows a standard immunisation schedule. A purified antigen, for example human immunoglobulin G for use in a precipitin test for species identification, is prepared in an adjuvant (a substance that amplifies the immune response by prolonging antigen release and stimulating APC activation). The adjuvant-antigen mixture is injected into the host animal at a defined primary site.

After a rest period during which a primary response develops, booster injections of the same antigen, this time often without adjuvant, are given at two to four week intervals. Blood samples are taken from the animal two to three weeks after each booster and tested for antibody titre using a simple double diffusion test or ELISA. When the titre reaches the target level, the animal is bled to collect antiserum. The antiserum may be used as collected (polyclonal antiserum), or the immunoglobulin fraction may be isolated by ammonium sulphate precipitation or affinity chromatography to produce a purified antibody preparation.

Polyclonal antisera contain antibodies against multiple epitopes of the target antigen, produced by many different B cell clones. They are resilient: if one epitope is degraded in an aged or contaminated forensic sample, other epitopes may still be recognised. However, they may also contain antibodies that cross-react with related antigens from other species, requiring adsorption steps to remove unwanted specificities before the antiserum is suitable for forensic use. Cross-reactivity is a known source of false-positive results in species identification tests and must be controlled by running appropriate negative controls.

Monoclonal antibodies (mAbs) overcome the variability inherent in polyclonal antisera by deriving from a single B cell clone. The technology, introduced by Kohler and Milstein in 1975, fuses an antigen-specific B cell from an immunised mouse with an immortal myeloma cell line to create a hybridoma. The hybridoma inherits the B cell's antibody specificity and the myeloma's ability to divide indefinitely. Cells are plated out individually, and wells containing hybridomas secreting the desired antibody specificity are identified by ELISA screening. Selected hybridoma lines are expanded and cryopreserved, providing an indefinite source of antibody with defined and reproducible specificity.

In forensic science, monoclonal antibodies are used where lot-to-lot consistency and defined epitope specificity are required. ELISA kits for the detection of prostate-specific antigen (PSA) in semen stains use monoclonal antibodies against a defined PSA epitope that is absent from other body fluids. Lateral-flow immunochromatographic strips for drugs of abuse screening use pairs of monoclonal antibodies: one labelled with colloidal gold to create a visible reporter complex, and one immobilised at the test line to capture the complex. The immune response mechanisms that produced these reagents, specifically affinity maturation and clonal selection, are the basis for the consistency and sensitivity that make these tests forensically defensible.

The biological source of a monoclonal antibody is ultimately the same as a polyclonal antiserum: an animal immunised with the target antigen, generating B cells through the primary and secondary immune responses described above. The difference is that hybridoma technology captures a single B cell clone at the peak of its affinity-matured state and immortalises it, whereas polyclonal antiserum captures the mixture of clones present in the blood at the time of collection.

Every immunoassay used in forensic analysis, from the Ouchterlony double diffusion precipitin test to the enzyme-linked immunosorbent assay, is an engineered exploitation of antigen-antibody binding. The sensitivity and specificity of these tests are functions of the antibody's binding affinity (a product of affinity maturation), the antibody's concentration (a product of clonal expansion and plasma cell activity), and the antibody's specificity (a product of clonal selection). Understanding why these properties vary between different antisera helps forensic scientists evaluate reagent quality, troubleshoot unexpected results, and assess the reliability of test outcomes.

The secondary immune response principle also explains the hook effect, an analytical artefact relevant to ELISA interpretation. When antigen concentration in a sample is extremely high, it can saturate all available antibody binding sites and prevent the formation of the antibody-antigen-antibody sandwich that generates the assay signal. The result is a paradoxically weak or negative result at very high antigen concentrations. Forensic analysts interpreting unexpected negative ELISA results on samples expected to contain high antigen concentrations should consider the hook effect and retest at serial dilutions.

Antibody class also determines which forensic assay formats are appropriate. IgM, with its pentameric structure and ten binding sites, is a more potent agglutinator than IgG on a per-molecule basis, because its multiple arms can bridge many antigen-coated particles simultaneously. This is why IgM alloantibodies (naturally occurring antibodies against blood group antigens, such as anti-A and anti-B) are detected by direct agglutination tests, while IgG alloantibodies (such as anti-D from Rh immunisation) require indirect methods like the indirect antiglobulin test (IAT) that add an anti-IgG bridging antibody to produce visible agglutination. The immunological logic behind these test design choices traces directly to the immune response mechanisms covered in this topic.

Across jurisdictions, forensic immunological evidence is admissible under the same general rules as other scientific evidence. In England and Wales, expert evidence must meet the reliability criteria under the Criminal Procedure Rules. In the United States, federal courts apply the Daubert standard, which requires that methods be scientifically validated and subject to peer review. In India, admissibility is governed by the Bharatiya Sakshya Adhiniyam 2023 (which replaced the Indian Evidence Act 1872), under which expert opinion is admissible as opinion evidence. The European Union's forensic science standards under the European Forensic Science Area framework also address method validation requirements. In all these systems, the quality of the antiserum reagent, its validation against cross-reactive species or antigens, and the laboratory's quality management procedures are the factors that determine whether an immunological test result is credible in court.